Unity Biotechnology, Inc. (UBX) SEC Filing 8-K Material Event for the period ending Friday, March 17, 2023

Unity Biotechnology, Inc.

CIK: 1463361 Ticker: UBX

View differences made from one to another to evaluate Unity Biotechnology, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Unity Biotechnology, Inc..


Assess how Unity Biotechnology, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Unity Biotechnology, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Unity Biotechnology, Inc. provided additional information to their SEC Filing as exhibits

Ticker: UBX
CIK: 1463361
Form Type: 8-K Corporate News
Accession Number: 0001193125-23-074071
Submitted to the SEC: Fri Mar 17 2023 5:14:01 PM EST
Accepted by the SEC: Fri Mar 17 2023
Period: Friday, March 17, 2023
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: